Current Treatment Options in Oncology最新文献

{"title":"Advanced Mucosal Melanoma Therapies: Current Status and Future Directions.","authors":"Yiqun Zhang, Dawei Zhao, Di Wu","doi":"10.1007/s11864-025-01372-y","DOIUrl":"10.1007/s11864-025-01372-y","url":null,"abstract":"<p><strong>Opinion statement: </strong>Mucosal melanoma (MM) represents a rare malignancy in Caucasian populations but constitutes one of the predominant melanoma subtypes among non-Caucasian ethnic groups. Due to its anatomic occult nature, a significant proportion of patients with MM present with advanced-stage disease at diagnosis. Characterized by distinct genomic profiles and an immunosuppressive tumor microenvironment, MM exhibits suboptimal responses to current targeted drugs and immune checkpoint inhibitors (ICIs). Combination immunotherapy can overcome immune evasion by enhancing the infiltration of tumor-specific antigen-reactive T lymphocytes, thereby exhibiting potentiated anti-tumor activity. However, the rarity of MM has posed significant barriers to better understanding immunotherapy resistance mechanisms and investigating novel therapies. Consequently, there is a critical unmet need for establishing standardized treatment guidelines to improve survival outcomes in advanced MM. This article comprehensively reviews current status in the treatment of advanced MM. It also discusses potential future directions for treatment based on recent advances from clinical trials and basic research.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13056740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147629012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Theranostics in Sarcoma: A Critical Review of Current Evidence and Future Potential.","authors":"Ojasvi Appana, David Konieczkowski, Gabriel Tinoco","doi":"10.1007/s11864-026-01386-0","DOIUrl":"10.1007/s11864-026-01386-0","url":null,"abstract":"&lt;p&gt;&lt;p&gt;OPINION STATEMENT: Sarcomas are rare, heterogeneous malignancies with over 100 subtypes and limited effective therapies in advanced stages. Theranostics, a strategy that combines diagnostic imaging and targeted radionuclide therapy using the same molecular target, has revolutionized care in cancers, including prostate and neuroendocrine tumors. This review evaluates the current evidence and future potential of theranostic applications in sarcoma. A comprehensive literature search was conducted across PubMed, Google Scholar, and clinicaltrials.gov for studies published between January 2010 and August 2025. Search terms included “theranostics,” “radionuclide,” “molecular imaging,” “sarcoma,” and molecular targets such as PSMA, FAPI, SSTR, PDGFR, and TEM-1. Eligible articles included clinical trials, cohort studies, and systematic reviews. Case reports were included only when higher-level evidence was lacking. Key theranostic targets in sarcoma include FAP, PSMA, SSTR, and PDGFR. Among these, FAP-directed agents demonstrate the most clinical maturity, with improved diagnostic performance compared to 18F-FDG and early evidence of disease control with 90Y/177Lu-labeled therapies. PSMA and SSTR expression in sarcomas is more variable and localized to tumor vasculature, with case-level therapeutic use and limited efficacy data. PDGFR and emerging targets, such as TEM-1, show biological promise but remain under investigation in early-phase studies. Theranostics represents a promising approach to individualized sarcoma treatment, with FAP-targeted agents showing the most advanced clinical development. FAP-based imaging improves lesion detection compared to standard 18F-FDG PET, and early therapeutic trials suggest disease control in select patients. However, broader validation and regulatory approval are needed before clinical integration. Theranostics represents a promising precision-medicine paradigm for sarcoma, linking diagnostic PET imaging with targeted radioligand therapy targeting a shared molecular target. With more than 100 histologic subtypes and limited effective treatment options in advanced disease, theranostics may provide a future therapeutic avenue for selected patients. Among currently investigated platforms, fibroblast activation protein-directed approaches are the most clinically advanced. 68Ga FAPI PET has demonstrated superior lesion detection compared with 18 F FDG across multiple sarcoma subtypes, and early studies of 90Y- and 177Lu-labeled FAPI agents report disease stabilization in selected patients with advanced disease, supporting biological and technical feasibility. In contemporary practice, FAP-directed imaging is best integrated within investigational frameworks to identify candidates for radioligand therapy, refine trial selection, and enable response monitoring in FAP-avid sarcomas. Other targets, including PSMA, SSTR, and PDGFR, remain exploratory and require prospective validation before clinical translation. Stan","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13021735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147522630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole Lung Irradiation in Ewing Sarcoma with Pulmonary Metastases: Critical Appraisal of Evolution, Evidence, and Future Pathways in Precision Oncology.","authors":"YuanYou Yang, Lu Xie, Jie Xu, Xin Sun, Gang Ren","doi":"10.1007/s11864-026-01387-z","DOIUrl":"10.1007/s11864-026-01387-z","url":null,"abstract":"<p><p>OPINION STATEMENT: Based on the cumulative evidence, we advocate for the continued use of whole lung irradiation (WLI) as an integral component of multimodal therapy for Ewing sarcoma patients with pulmonary metastases, particularly in those with isolated lung involvement. Modern cardiac-sparing techniques, such as intensity-modulated radiotherapy and proton therapy, should be prioritized to mitigate acute cardiopulmonary toxicity, despite the unknown long-term implications of the low-dose bath. Dose prescription should be individualized according to age, risk stratification, and response to chemotherapy, with 15–18 Gy in 1.5 Gy fractions representing the current standard. For patients achieving a rapid complete radiographic response, the decision to omit WLI must be balanced against the proven survival benefit and should ideally be guided by emerging biomarkers, pending prospective validation. Concurrent administration of WLI with novel systemic agents, including tyrosine kinase inhibitors and immune checkpoint inhibitors, is not recommended outside clinical trials due to the risk of synergistic pulmonary toxicity. Lifelong surveillance for secondary malignancies and cardiopulmonary late effects is mandatory. We believe that the field must now move beyond empirical application toward biologically adapted, risk-adapted precision radiotherapy.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13018070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147516427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transforming a Roadblock into a Roadmap: Evolving HFSR Management From Adverse Event to Efficacy Biomarker.","authors":"Qian Xu, Jinhan Chen, Huiwen Sun, Xingyu Liu, Fangmin Zhao, Qijin Shu","doi":"10.1007/s11864-026-01385-1","DOIUrl":"10.1007/s11864-026-01385-1","url":null,"abstract":"<p><p>OPINION STATEMENT: Hand-foot skin reaction (HFSR) is one of the most common adverse events associated with multi-target tyrosine kinase inhibitors (mTKIs), particularly vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs), and has traditionally been regarded as a dose-limiting toxicity. However, a growing body of evidence suggests that the occurrence of HFSR may be associated with improved clinical efficacy, prompting a reevaluation of its clinical significance. This review aims to systematically synthesize the literature on the pathogenesis of HFSR, clinical efficacy data from randomized controlled trials (RCTs), and emerging therapeutic concepts in the evolution of management strategies. We found that the occurrence of HFSR exhibits a clear dose-dependent pattern, and the development of high-grade HFSR may be closely associated with favorable clinical efficacy. Therefore, we propose that HFSR could serve as a predictive biomarker for the efficacy of mTKIs-based cancer targeted therapy. HFSR is undergoing a fundamental paradigm shift from a “roadblock to dose adjustment” to a “roadmap for efficacy guidance”, which may intend to provide a comprehensive reference for clinical practice and future research, and facilitate the innovative development of HFSR management strategies in cancer therapy.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147475892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Menin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid Leukemia.","authors":"Daniel T Peters, Jess Hatfield, Mollie Reese, Joshua F Zeidner","doi":"10.1007/s11864-025-01378-6","DOIUrl":"10.1007/s11864-025-01378-6","url":null,"abstract":"<p><p>OPINION STATEMENT: Menin is involved in protein-protein interactions that are critical in the leukemogenesis of AML, particularly in patients with KMT2A rearrangements (KMT2Ar) and mutations in NPM1 (NPM1m). Revumenib is a first-in-class menin inhibitor approved by the U.S. Food and Drug Administration (FDA) in November 2024 for relapsed/refractory (R/R) acute leukemia with KMT2Ar. Revumenib was subsequently FDA-approved in October 2025 for R/R NPM1m AML, followed by approval of another oral menin inhibitor, ziftomenib, for R/R NPM1m AML in November 2025. These agents, along with other investigational menin inhibitors including bleximenib and enzomenib are being investigated in ongoing clinical trials as both single-agents and in combination with other chemotherapy agents in AML. Menin inhibitors have demonstrated clinical activity as single agents in KMT2Ar and NPM1m AML. However, the pharmacokinetics, safety profile, and selective activity varies among the available and investigational menin inhibitors. Despite these encouraging results, resistance mechanisms have been identified via mutations of the MEN1 gene and structural mutations in the menin binding pocket. As current and future clinical trials are completed, menin inhibitors are likely to play a large role in frontline and R/R treatment in KMT2Ar and NPM1m AML with likely expansion into populations of other genetic abnormalities.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147475937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole Abdominal Radiotherapy in Bone and Soft Tissue Sarcomas: Indications, Techniques, Clinical Outcomes, and Future Directions.","authors":"YuanYou Yang, Lu Xie, Xin Sun, Jie Xu, Gang Ren","doi":"10.1007/s11864-026-01384-2","DOIUrl":"10.1007/s11864-026-01384-2","url":null,"abstract":"<p><p>OPINION STATEMENT: Managing bone and soft tissue sarcomas at high risk of intra-abdominal spread remains clinically challenging, and whole abdominal radiotherapy (WART) has become a pivotal locoregional component of multimodal therapy. For desmoplastic small round cell tumor (DSRCT)—the primary indication for WART—our practice prioritizes integrating WART with complete cytoreductive surgery and alkylator-based chemotherapy, with intensity-modulated radiotherapy (IMRT) or helical tomotherapy strongly recommended as preferred techniques due to their significant reduction in hematologic and gastrointestinal toxicity versus conventional 2D radiotherapy while preserving target coverage. For other subtypes (peritoneal rhabdomyosarcoma, Ewing sarcoma, myxoid liposarcoma), WART should be individualized: considered for confirmed peritoneal dissemination, residual disease post-chemotherapy, or incomplete resection, but avoided in extensive distant metastases. Future paradigms must optimize benefit-to-toxicity ratios, including routine proton/carbon ion therapy for pediatric/young adult patients to minimize late effects (e.g., growth abnormalities, infertility), exploration of WART combinations with targeted agents (e.g., IGF-1R inhibitors) or immunotherapies (e.g., PD-1/PD-L1 inhibitors) in prospective trials given promising preclinical/early clinical data, and use of molecular profiling and circulating tumor DNA (ctDNA) monitoring to guide patient selection and timely treatment adjustments. Long-term follow-up is essential for all patients to monitor late toxicities (e.g., small bowel obstruction, radiation nephritis) and secondary malignancies. In summary, WART is a cornerstone of curative-intent treatment for selected intra-abdominal sarcomas, but requires rigorous patient selection, advanced planning, and integration with systemic therapies, with continued international collaboration and trials critical to refining its role and improving outcomes for these rare, aggressive malignancies.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12987878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147460992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of Targeted Therapy in Pediatric Acute Lymphoblastic Leukemia: Exploring Novel Approaches and Emerging Therapies.","authors":"David J Byrwa, Marissa Krieger, Lisa M Niswander, Kara M Kelly","doi":"10.1007/s11864-025-01376-8","DOIUrl":"10.1007/s11864-025-01376-8","url":null,"abstract":"<p><strong>Opinion statement: </strong>With modern risk stratification of multi-agent cytotoxic chemotherapy protocols, we now cure the majority of patients with pediatric acute lymphoblastic leukemia (ALL). However, patients with high-risk features or relapsed disease continue to have suboptimal outcomes. Conventional chemotherapy agents may increase long term organ toxicities even in more favorable patients. Improved understanding of the molecular characteristics of pediatric ALL has led to the preclinical and clinical development of more targeted and less systemically toxic therapeutic options for patients with ALL. Agents such as blinatumomab, inotuzumab ozogamicin, tisagenlecleucel and several others have revolutionized the treatment of relapsed or refractory ALL by either directing therapies locally to leukemic cells or by targeting specific leukemogenic pathways. Here we present current evidence for efficacy and toxicity profiles for these targeted therapies in pediatric patients with ALL. Many of these strategies have been more comprehensively studied in the adult population and we will highlight ongoing and needed clinical trials in pediatrics. We need to overcome our historically delayed approach to introducing new therapeutic options in pediatrics, as adults often benefit from innovations for years before they are evaluated in children. More proactively incorporating these emerging treatments into frontline therapy for the most vulnerable, high-risk pediatric ALL populations could meaningfully reshape our treatment paradigm. Earlier collaboration for development of clinical trials across pediatric and adult ALL may facilitate more rapid access to promising agents. We anticipate that successful upfront integration of more targeted approaches will improve response rates, reduce reliance on highly toxic chemotherapies and ultimately increase the likelihood of duration of remission. We expect the next generation of clinical trials will credential more targeted therapies for use in frontline therapy with the goal of improved outcomes with minimized toxicity for all patients with pediatric ALL, not just those with more favorable disease characteristics.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12929260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147272652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endocrinologic Toxicities of Cancer Therapy: Evolving Challenges and Multidisciplinary Approaches.","authors":"Tugce Akcan, Angela N Rao, Afreen Idris Shariff","doi":"10.1007/s11864-025-01375-9","DOIUrl":"10.1007/s11864-025-01375-9","url":null,"abstract":"<p><p>OPINION STATEMENT: Modern cancer therapies, particularly immune checkpoint inhibitors (ICIs), have led to a rise in endocrine toxicities such as hypothyroidism, adrenal insufficiency, insulin-dependent diabetes, and hypophysitis. These conditions often present with nonspecific symptoms such as fatigue, which can make timely diagnosis challenging, especially in patients with advanced malignancies. Early recognition is essential, as most endocrinopathies are treatable with hormone replacement and rarely require discontinuation of cancer therapy. This review highlights emerging trends in endocrine toxicities associated with cancer treatment, discusses the challenge of distinguishing symptoms from these toxicities from cancer progression, and examines the shared roles of oncology, endocrinology, and palliative care in patient management from symptom to diagnosis. We propose a multidisciplinary approach to support care across the treatment continuum, with an emphasis on shared decision-making. Continued research is needed to establish standardized clinical guidelines, integrate digital health innovations, and improve long-term outcomes.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146259708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paracetamol and NSAIDs in Cancer Pain Management: Evidence Review and Treatment Considerations.","authors":"Kate Hanwell, Anna Bradley, Jason W Boland","doi":"10.1007/s11864-025-01368-8","DOIUrl":"10.1007/s11864-025-01368-8","url":null,"abstract":"<p><p>OPINION STATEMENT: Pain is one of the most prevalent and distressing symptoms in cancer, affecting up to 90% of patients and significantly impairing quality of life. Paracetamol (acetaminophen) and non-steroidal anti-inflammatory drugs (NSAIDs) are widely recommended by international guidelines for the management of non-surgical cancer pain, either alone or as adjuvants to opioids. In this paper, the current evidence for their efficacy, tolerability, and safety in this setting is reviewed. Evidence for paracetamol in cancer pain remains limited and of low quality. Small trials and systematic reviews suggest little or no additional analgesic benefit when used alongside strong opioids, and no clear advantage of intravenous over oral paracetamol has been demonstrated. Evidence for NSAIDs is slightly stronger, with studies indicating analgesic benefit both as monotherapy and in combination with opioids, although the quality of evidence is again restricted by small sample sizes, heterogeneity, and outdated trials. Concerns regarding adverse effects, particularly gastrointestinal, renal, and cardiovascular, often limit use, athough short-term use in patients receiving palliative care may be safer than historically perceived. Comparative data between individual NSAIDs, routes of administration, and longer-term use are lacking. Overall, while both paracetamol and NSAIDs are commonly prescribed and theoretically beneficial, high-quality, adequately powered studies in patients with cancer pain are scarce. Further research is needed to evidence their role, especially in opioid-sparing strategies, as well as determining the relative clinical effectiveness and harm of individual NSAIDs in patients with non-surgical cancer pain.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":"11"},"PeriodicalIF":5.8,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12901147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146167844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding, Recognizing, and Managing Cancer-Related Fatigue Associated with Breast Cancer.","authors":"LanQing Peng, XiaoMin Wang, ChenRu Zhang, Tao Liu, Xin Luo, ZhuoHong Li","doi":"10.1007/s11864-026-01381-5","DOIUrl":"10.1007/s11864-026-01381-5","url":null,"abstract":"<p><p>OPINION STATEMENT: In the treatment plan of breast cancer-related Cancer-related fatigue(CRF), non-drug intervention is the core, and physical exercise can improve the physical fitness and fatigue state of patients. Personalized nutritional support can correct energy imbalance and relieve malnutrition related fatigue. Psychological intervention such as cognitive behavioral therapy can regulate neuroendocrine and inflammatory responses and reduce fatigue induced by psychological factors, and the effect of multimodal combined intervention is better than that of single measure.However, there are some areas that can be optimized. First, drug therapy is rarely mentioned, and drug intervention for patients with moderate to severe CRF is not explored. Second, the characteristics of CRF in different breast cancer subtypes are different, and the existing protocols do not fully reflect the subtype specificity. Third, the adaptation of the intervention in the scenario of primary medical care is insufficient. Telemedicine and wearable devices can be combined to improve the accessibility of the program. In the future, it is necessary to further improve the synergistic mechanism of drugs and non-drugs and refine the subtype-specific scheme to achieve more accurate management of CRF.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":"9"},"PeriodicalIF":5.8,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146167830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}